Besides their direct cytotoxicity against HER2+ BCCs, anti-HER2 mAbs have also proven to stimulate anti-cancer immunity through antibody-dependent cell cytotoxicity (ADCC)3,4. This evidence concerns the gene ERBB2 and cancer.